Targeting Risk Beyond Lipids
Expert Discussions: Moving Beyond Lipid Lowering to Lower Risk in ASCVD and CKD

Released: August 26, 2024

Expiration: August 25, 2025

Erin Michos
Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Mark J. Sarnak
Mark J. Sarnak, MD, MS

Activity

Progress
1
Course Completed

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.   

 Episode outline:   

  • Moving beyond lipid lowering to address residual inflammatory risk
  • Novel anti-inflammatory targets for ASCVD
    • NLRP3 inflammasome
    • hsCRP as a standard inflammatory biomarker
    • Other potential therapeutic targets: IL-1β, IL-6, TNF-α

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below: